{'fraction_non_alphanumeric': 0.024232633279483037, 'fraction_numerical': 0.0, 'mean_word_length': 5.391752577319588, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
New perspectives in the treatment of prostate cancer.

Current androgen ablation therapies for advanced prostate cancer are not curative. Several recently identified critical biochemical pathways, including the E-cadherin/catenin complex, programmed cell death, telomerase activity, and receptor kinases, may represent targets for new therapeutic approaches. Different forms of gene therapy are also being investigated. Drug development is at the pre-clinical stage, but phase I and II clinical trials are planned, and may lead to a wider choice of therapeutic options for prostate cancer in the not too distant future.